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Supplementary	Tables	
	
Supplementary	Table	S1. Summary	of	AF	cases	and	referents	by	ancestry	
	
Ancestry	 AF		 Referents	
European	 55,114	 482,295	
Japanese	 8,180	 28,612	
African	American	 1,307	 7,660	
Brazilian	 568	 1,096	
Hispanic	 277	 3,081	
Total	 65,446	 522,744	
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Supplementary	Table	S2.	Additional	novel	loci	in	combined	and	European	ancestry	meta-analysis	with	traditional	P-value	cutoff	(5	x	10-8)	
	
Sentinel	
Variant	 Chr	 hg19	
Risk/Ref	
Allele	
RAF	
[%]	 RR	 95%	CI	 P-value	 Nearest	Gene(s)	 Func	
Imp	
Qual	 I
2	 PHET	
Combined	ancestry	
rs12992412	 2	 148792665	 T/A	 38	 1.04	 1.03-1.06	 2.30E-08	 MBD5	 intronic	 0.99	 0	 4.78E-01	
rs73032363	 3	 24472866	 A/G	 70	 1.04	 1.03-1.06	 3.59E-08	 THRB	 intronic	 0.98	 0	 6.89E-01	
rs1307274	 6	 34240576	 T/G	 8	 1.08	 1.05-1.11	 3.85E-08	 C6orf1,NUDT3	 regulatory	reg.	 0.92	 0	 8.76E-01	
rs6907805	 6	 87856003	 G/T	 51	 1.04	 1.03-1.06	 1.10E-08	 CGA,ZNF292	 intergenic	 0.98	 0	 4.14E-01	
rs12208899	 6	 133474303	 A/G	 21	 1.05	 1.03-1.07	 1.95E-08	 LINC00326,EYA4	 intergenic	 0.98	 0	 4.22E-01	
rs11768850	 7	 876227	 T/C	 42	 1.04	 1.03-1.05	 4.96E-08	 SUN1	 intronic	 0.98	 0	 4.14E-01	
rs55985730	 7	 128417044	 G/T	 6	 1.10	 1.06-1.14	 1.81E-08	 OPN1SW	 upstream	 0.87	 0	 8.05E-01	
rs7460121	 8	 135812416	 A/G	 10	 1.07	 1.05-1.10	 1.65E-08	 MIR30B	 downstream	 0.92	 0	 7.04E-01	
European	ancestry	
rs9872035	 3	 196494702	 C/T	 45	 1.04	 1.03-1.06	 1.80E-08	 PAK2	 intronic	 0.97	 	 	
rs210632	 6	 117880342	 A/G	 25	 1.05	 1.03-1.07	 2.75E-08	 GOPC	 downstream	 1	 	 	
Abbreviations,	Chr,	chromosome,	CI,	confidence	interval,	Func,	functional	consequence	(most	severe	consequence	by	variant	effect	predictor),	
HET,	heterogeneity,	I2,	I-square,	impQual,	average	imputation	quality,	P,	P-value,	RR,	relative	risk,	RAF,	risk	allele	frequency.
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Supplementary	Table	S3. Known	loci	in	combined	ancestry	meta-analysis	
Enclosed	electronic	excel	file	
Supplementary	Table	S4.	Gene	set	enrichment	analysis	results	for	combined	ancestry	meta-
analysis	
Enclosed	electronic	excel	file	
Supplementary	Table	S5.	Novel	and	known	loci	in	ancestry	specific	meta-analyses	
Enclosed	electronic	excel	file		
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Supplementary	Table	S6.	Proportion	of	heritability	explained	by	AF	loci	
Study	
AF-loci	h2g	
observed	
(SE)	
AF-loci	h2g		
liability	
scale	(SE)	
Overall	h2g	
liability	
scale	
Proportion	
explained	
[%]	
25	AF	loci		
(EUR	ancestry	loci	Christophersen	et	al.)1	
0.00744	
(0.00081)	
0.0533	
(0.00579)	 0.2156	 24.74	
84	AF	loci		
(EUR	ancestry	loci	from	Roselli	et	al.)	
0.01262	
(0.00121)	
0.0905	
(0.00868)	 0.2140	 42.28	
Abbreviations,	AF,	atrial	fibrillation,	EUR,	European,	h2g,	SNP-heritability,	SE,	standard	error.	
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Supplementary	Table	S7.	Loci	with	multiple	signals	identified	by	conditional	and	joint	analysis	
for	European	ancestry	meta-analysis	
Enclosed	electronic	excel	file	
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Supplementary	Table	S8.	Sentinel	variants	or	proxies	with	missense	consequence,	for	loci	from	combined	ancestry	meta-analysis		
	
	
Sentinel	
Variant	
Sentinel	
MAF	[%]	 Proxy	
Proxy	
MAF	[%]	 LD	[r
2]	 Location	 Gene	
Consequence	
coding	
sequence	
Consequence	
protein	
sequence	
#	In	silico	
predicted	as	
damaging*	
Novel	loci	 	
rs187585530	 0.5	 -	 -	 -	 1:10167425	 UBE4B	 c.1342G>A	 p.Gly448Arg	 -	
rs4484922	 31.7	 rs4074536	 31.7	 1.000	 1:116310967	 CASQ2	 c.196A>G	 p.Thr66Ala	 0	
rs72926475	 13.0	 rs34605051	 15.7	 0.671	 2:86693826	 KDM3A	 c.1339T>C	 p.Ser447Pro	 1	
rs2306272	 31.8	 -	 -	 -	 3:66434643	 LRIG1	 c.1843A>G	 p.Met615Val	 0	
rs3822259	 32.1	 rs13441	 32.4	 0.724	 4:10099340	 WDR1	 c.553A>G	 p.Ile185Val	 0	
rs10760361	 35.3	 rs4574	 42.5	 0.756	 9:127177161	 PSMB7	 c.116T>C	 p.Val39Ala	 0	
rs7919685	 46.7	 rs1935	 48.1	 0.861	 10:64927823	 JMJD1C	 c.7605G>C	 p.Glu2535Asp	 1	
rs7978685	 27.9	 rs2958149	 27.7	 0.999	 12:57109792	 NACA	 c.2063T>C	 p.Leu688Pro	 0	
rs12298484	 32.6	 rs11057401	 30.7	 0.906	 12:124427306	 CCDC92	 c.208A>T	 p.Ser70Cys	 4	
Known	loci	 	
rs35504893	 24.8	 rs3731746	 23.2	 0.846	 2:179430997	 TTN	 c.79862C>T	 p.Thr26621Met	 2	
rs6810325	 36.6	 rs11718898	 36.5	 0.996	 3:12848822	 CAND2	 c.230T>C	 p.Val77Ala	 0	
rs6790396	 39.2	 rs6795970	 38.0	 0.929	 3:38766675	 SCN10A	 c.3227T>C	 p.Val1076Ala	 0	
rs60212594	 14.7	 rs60632610	 14.7	 0.998	 10:75415677	 SYNPO2L	 c.4G>A	 p.Gly2Ser	 3	
Abbreviations,	Ala,	alanine	Arg,	arginine,	Asp,	asparagine,	Cys,	cysteine,	Glu,	glutamine,	Gly,	glycine,	Leu,	leucine,	LD,	linkage	disequilibrium,	
MAF,	minor	allele	frequency,	Met,	methionine,	Pro,	proline,	Ser,	serine,	Thr,	threonine,	Val,	valine.	*Assessed	by	5	prediction	algorithms:	
MutationTaster	(disease	causing	automatic	or	disease	causing),	SIFT	(damaging),	LRT	(deleterious),	Polyphen2	prediction	based	on	HumDiv	
(probably	damaging	or	possibly	damaging),	Polyphen2	prediction	based	on	HumVar	(probably	damaging	or	possibly	damaging).	
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Supplementary	Table	S9.	Chromatin	states	for	sentinel	variants	and	proxies	from	Roadmap	
Epigenomics	across	all	tissues	and	heart	
Enclosed	electronic	excel	file	
Supplementary	Table	S10.	Significant	cis-eQTLs	for	sentinel	variants	from	combined	ancestry	
meta-analysis	in	left	atrial	tissue	from	MAGNet	
	
Sentinel	
Variant	 Chr	 hg	19	 Gene	 Effect	 P-value	 FDR	
Effect/Ref	
Allele	
Novel	loci	
rs4484922	 1	 116310818	 CASQ2	 0.72	 5.29E-05	 4.71E-02	 C/G	
rs4855075	 3	 179170494	 GNB4	 1.24	 2.61E-12	 <1.00E-05	 T/C	
rs34969716	 6	 18210109	 TPMT	 0.91	 6.73E-07	 1.72E-03	 A/G	
rs12298484	 12	 124418674	 CCDC92	 0.67	 8.40E-06	 1.22E-02	 T/C	
rs10873299	 14	 77426711	
LINC01629	 1.02	 2.20E-20	 <1.00E-05	 A/G	
RP11-7F17.1	 0.77	 9.63E-12	 <1.00E-05	 A/G	
rs12908004	 15	 80676925	
ARNT2	 1.06	 4.62E-09	 <1.00E-05	 G/A	
RP11-210M15.2	 1.00	 3.51E-08	 1.65E-04	 G/A	
LINC01314	 0.85	 3.93E-06	 6.74E-03	 G/A	
rs242557	 17	 44019712	 MAPT	 0.91	 1.76E-12	 <1.00E-05	 A/G	
Known	loci	
rs2540949	 2	 65284231	 CEP68	 0.69	 9.40E-07	 2.21E-03	 A/T	
rs60212594	 10	 75414344	 MYOZ1	 1.49	 1.18E-11	 <1.00E-05	 C/G	
Abbreviations:	Chr,	chromosome,	eQTL,	expression	quantitative	trait	locus,	FDR,	false	
discovery	rate,	Ref,	reference.	
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Supplementary	Table	S11.	Significant	cis-eQTLs	for	sentinel	variants	from	combined	ancestry	
meta-analysis	in	GTEx	heart	tissues	
Enclosed	electronic	excel	file	
Supplementary	Table	S12.	Probable	AF	susceptibility	genes	for	loci	from	combined	ancestry	
meta-analysis	
Enclosed	electronic	excel	file	
Supplementary	Table	S13.	MetaXcan	results	based	on	summary	level	data	from	combined	
ancestry	meta-analysis	
Enclosed	electronic	excel	file	
Supplementary	Table	S14.	Association	to	diseases	and	traits	in	NHGRI-EBI	GWAS	catalog	for	
sentinel	variants	or	proxies	from	combined	ancestry	meta-analysis	
Enclosed	electronic	excel	file	
Supplementary	Table	S15.	PheWAS	results	in	UK	Biobank	for	sentinel	variants	from	combined	
ancestry	meta-analysis	
Enclosed	electronic	excel	file	
Supplementary	Table	S16.	134	loci	associated	with	atrial	fibrillation	
Enclosed	electronic	excel	file	
Supplementary	Table	S17.	Baseline	summary	for	GWAS	
Enclosed	electronic	excel	file	
Supplementary	Table	S18.	GWAS	summary	on	genotyping,	QC,	imputation	and	analysis	per	
study	
Enclosed	electronic	excel	file	
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Supplementary	Table	S19.	Pre-Imputation	quality	control	guidelines	
	
Sample	based	filters	
Check	for	per	sample	completeness	(e.g.	sample	call-rate	≥95%)	
Check	for	per	sample	heterozygosity	(e.g.	heterozygosity	should	be	
within	mean	±	3s.d.)	
Inspection	of	principal	component	or	multi-dimensional	scaling	plots	
(exclude	genetic	ancestry	outliers)	
Removal	of	related	individuals	or	account	for	relatedness	in	the	
statistical	model	
Variant	based	filters	
Exclusion	of	markers	when:	
Low	genotype	completeness	(e.g.	SNP	call	rate	<98%)	
Clear	deviations	from	Hardy-Weinberg	proportions	(e.g.	Hardy	Weinberg	
Equilibrium	P-value	in	controls	<	1x10-6)	
High	discordance	rates	
Excess	of	Mendelian	inconsistencies	(if	parent-offspring	pairs	available)	
Rare	variants	(e.g.	minor	allele	frequency	<0.5%	or	<1%)	
	
	
Supplementary	Table	S20.	Clinical	characteristics	of	MAGNet	samples	
Characteristics	 Left	atria	(n=101)	
Women,	n	(%)	 57	(56.4%)	
Age,	mean	[years]	±	SD	 59±12	
Weight,	mean	[kg]	±	SD	 82±22	
Height,	mean	[cm]	±	SD	 167±17	
Hypertension,	n	(%)	 60	(59.4%)	
Diabetes,	n	(%)	 20	(19.8%)	
History	of	atrial	fibrillation,	n	(%)	 14	(13.9%)	
Abbreviations,	cm,	centimeter,	kg,	kilogram,	SD,	standard	deviation.
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Supplementary	Table	S21.	Phenotype	definitions	for	UK	Biobank	PheWAS	
Phenotype	 Definition	
Bradyarrhythmia	 1)	Non-cancer	illness	code,	self-reported	(1486)	or		
2)	Diagnoses	–	main/secondary	ICD10	(I44,	I44.0-7,	I45.0-5,	I49.5)	or	
3)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(I44,	I44.0-7,	I45.0-5,	I49.5)	or	
4)	Diagnoses	–	main/secondary	ICD9	(426.0,	426.1,	426.3,	426.4,	426.5,	426.6)	or	
5)	Operation	code	(1096,	1548,	1549)	or		
6)	Pacemaker	(Yes)	or	
7)	Operative	procedures	–	main/secondary	OPCS	(K60,	K60.1-9,	K61,	K61.1-9)	
Coronary	Artery	
Disease		
1)	Operative	procedures	–	main/secondary	OPCS	(K40.1-4,	K41.1-4,	K45.1-5,	K49.1-2,	K49.8-9,	K50.2,	K75.1-4,	
K75.8-9)	or	
2)	Source	of	first	myocardial	infarction	report	(Self-reported	only,	Hospital	admission,	Death	only)	
Type	II	Diabetes	 1)	Non-cancer	illness	code,	self-reported	(1223)	or	
2)	Diagnoses	–	main/secondary	ICD10		(E11,	E11.0-9)	or		
3)	Underlying	(primary/secondary)	cause	of	death:	ICD10	(E11,	E11.0-9)	
Heart	Failure	 1)	Non-cancer	illness	code,	self-reported	(1076,	1079)	or	
2)	Diagnoses	–	main/secondary	ICD10	(I11.0,	I13.0,	I13.2,	I25.5,	I42.0,	I42.5,	I42.8-9,	I50,	I50.0,	I50.1,	I50.9)	or	
3)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(I11.0,	I13.0,	I13.2,	I25.5,	I42.0,	I42.5,	
I42.8-9,	I50,	I50.0,	I50.1,	I50.9)	or	
4)	Diagnoses	–	main/secondary	ICD9	(425.4,	428.0,	428.1,	428.9)		
and	exclude:	
1)	Non-cancer	illness	code,	self-reported	(1588)	or	
2)	Diagnoses	–	main/secondary	ICD10	(I42.1-2)	or	
3)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(I42.1-2)	
Hypercholesterolemia	 1)	Non-cancer	illness	code,	self-reported	(1473)	or	
2)	Diagnoses	–	main/secondary	ICD10	(E78.0-2,	E78.4-5)	or	
3)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(E78.0-2,	E78.4-5)	
Hypertension	 1)	Non-cancer	illness	code,	self-reported	(1065,	1072)	or	
2)	Vascular/heart	problems	diagnosed	by	doctor	(High	blood	pressure)	or	
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3)	Diagnoses	–	main/secondary	ICD10	(I10,	I11,	I11.0,	I11.9,	I12,	I12.0,	I12.9,	I13,	I13.0-2,	I13.9,	I15,	I15.0-2,	
I15.8-9)	or	
4)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(I10,	I11,	I11.0,	I11.9,	I12,	I12.0,	I12.9,	I13,	
I13.0-2,	I13.9,	I15,	I15.0-2,	I15.8-9)	or	
5)	Diagnoses	–	main/secondary	ICD9	(401,	401.0,	401.1,	401.9,	402,	402.0,	402.1,	402.9,	403,	403.0,	403.1,	
403.9,	404,	404.0,	404.1,	404.9,	405,	405.0,	405.1,	405.9)	
Mitral	regurgitation	 1)	Non-cancer	illness	code,	self-reported	(1585)	or	
2)	Diagnoses	–	main/secondary	ICD10	(I05.1-2,	I34.0)	or	
3)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(I05.1-2,	I34.0)	or	
4)	Diagnoses	–	main/secondary	ICD9	(3942)	or	
5)	Operative	procedures	–	main/secondary	OPCS	(K34.1)	
Peripheral	vascular	
disease	
1)	Non-cancer	illness	code,	self-reported	(1067,	1087,	1088)	or	
2)	Operation	code	(1102,	1108,	1440)	or	
3)	Diagnoses	–	main/secondary	ICD10	(I70.0,	I70.00-01,	I70.2,	I70.20-21,	I70.8,	I70.80,	I70.9,	I70.90,	I73.8-9)	or	
4)	Underlying	primary/Contributing	secondary	cause	of	death:	ICD10	(I70.0,	I70.00-01,	I70.2,	I70.20-21,	I70.8,	
I70.80,	I70.9,	I70.90,	I73.8-9)	or	
5)	Diagnoses	–	main/secondary	ICD9	(440.0,	440.2,	443.8,	443.9)	or	
6)	Operative	procedures	–	main/secondary	OPCS	(X09.3-5,	L21.6,	L51.3,	L51.6,	L51.8,	L52.1-2,	L54.1,	L54.4,	
L54.8,	L59.1-8,	L60.1-2,	L63.1,	L63.5,	L63.9,	L66.7)	
Stroke	 Source	of	first	stroke	report	(Self-reported	only,	Hospital	admission,	Death	only)	
Smoking		 Smoking	status	at	first	visit	(Never	versus	Previous	or	Current)		
BMI	 Body	mass	index	at	first	visit	
Height	 Standing	height	at	first	visit	(exclude	if	<120cm)	
Abbreviations:	ICD,	international	classification	of	diseases	and	related	health	problems,	OPCS,	office	of	population	censuses	and	surveys:	
classification	of	interventions	and	procedures.	
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Supplementary	Table	S22.	Summary	of	cases,	referents	and	sample	size	for	phenotypes	in	UK	
Biobank	PheWAS	
Phenotype	 #	Cases	 #	Referents	 Sample	size	
Body-mass	index	 -	 -	 393,038	
Height	 -	 -	 393,485	
Bradyarrhythmia	 8,072	 386,333	 394,405	
Coronary	artery	disease	 20,397	 374,018	 394,415	
Heart	failure	 6,504	 387,652	 394,156	
Hypercholesterolemia	 73,382	 321,074	 394,456	
Hypertension	 134,901	 259,611	 394,512	
Mitral	regurgitation	 2,372	 392,042	 394,414	
Peripheral	vascular	disease	 5,117	 389,291	 394,408	
Smoking	[ever]	 186,224	 206,678	 392,902	
Stroke	 9,927	 384,489	 394,416	
Type	II	Diabetes	 19,744	 374,670	 394,414	
Abbreviations:	PheWAS,	phenome-wide	association	study.	
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Supplementary	Figures	
	
Supplementary	Figure	S1.	Quantile-Quantile	plot	of	combined	ancestry	meta-analysis	
	
Quantile-Quantile	plot	of	combined	ancestry	meta-analysis	for	12,149,979	included	variants	and	
λGC	=	1.0948.	
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Supplementary	Figure	S2.	Venn	diagram	for	genes	near	sentinel	variants	from	combined	
ancestry	meta-analysis	within	enriched	gene	sets,	by	functional	groups	
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Supplementary	Figure	S3.	Manhattan	plot	of	European	ancestry	meta-analysis	
	
	
The	plot	shows	novel	(red	and	purple)	and	known	(blue)	genetic	loci	associated	with	AF	at	a	
significance	level	of	P	<	1x10-8	(dashed	line),	for	the	European	ancestry	meta-analysis.	Loci	in	
purple	did	not	reach	genome-wide	significance	in	the	combined	ancestry	meta-analysis.	Gene	
labels	correspond	to	the	nearest	gene(s).	The	y-axis	has	a	break	between	–log10(P)	of	25	and	
400	to	emphasize	the	novel	loci.	
CDK6 
GOSR2, 
MIR5089 
EPHA3, 
PROS1 
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Supplementary	Figure	S4.	Quantile-Quantile	plot	of	European	ancestry	meta-analysis
	
Quantile-Quantile	plot	of	European	ancestry	meta-analysis	for	9,362,422	included	variants	and	
λGC	=	1.1194.	
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Supplementary	Figure	S5.	Manhattan	plot	of	African	American	meta-analysis	
	
	
	
The	plot	shows	known	(blue)	genetic	loci	associated	with	AF	at	a	significance	level	of	P	<	1x10-8	
(dashed	line),	for	the	African	American	ancestry	meta-analysis.	The	gene	label	corresponds	to	
the	nearest	genes.	
	
	
	
PITX2,C4orf32 
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Supplementary	Figure	S6.	Quantile-Quantile	plot	of	African	American	ancestry	meta-analysis	
	
Quantile-Quantile	plot	of	African	American	ancestry	meta-analysis	for	8,640,046	included	
variants	and	λGC	=	0.997.	
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Supplementary	Figure	S7.	Regional	plots	for	4q25	for	European,	Japanese	and	African	
American	ancestry	
	
	
	
	
Regional	plots	of	4q25	created	with	LocusZoom2,	for	European	ancestry	results	(a),	Japanese	
ancestry	results	(b)	and	African	American	ancestry	results	(c).	LD	is	shown	based	on	1000	
Genomes	phase	1	v3	reference,	using	the	populations	EUR	(a),	ASN	(b)	and	AFR	(c).	Panel	d	
shows	the	pairwise	LD	(r2)	for	the	sentinel	variants	based	on	the	1000	Genomes	phase	1	v3	
reference	for	each	ancestry,	calculated	with	SNiPA3.	Abbreviations,	1000G,	1000	Genomes,	AA,	
African	American,	AFR,	African,	ASN,	Asian,	EUR,	European,	JAP,	Japanese,	LD,	linkage	
disequilibrium.	
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Supplementary	Figure	S8.	Forest	plots	of	odds	ratios,	and	allele	frequency	plots,	by	ancestry	
for	sentinel	variants	with	significant	heterogeneity	
	
	
	
	
Forest	plots	of	odds	ratios	and	pie	charts	of	allele	frequencies	across	ancestries	for	sentinel	
variants	with	significant	heterogeneity,	close	to	PITX2	(a),	NEURL	(b),	and	ZFHX3	(c).	Shown	are	
odds	ratios	with	95%	confidence	intervals.	Frequencies	of	the	effect	allele	are	depicted	in	blue,	
frequencies	of	the	reference	allele	are	depicted	in	orange.	Abbreviations,	AA,	African	American,	
BRAZ,	Brazilian,	EUR,	European,	HISP,	Hispanic,	JAP,	Japanese.	
	
c      rs2359171 (ZFHX3)   
a      rs2129977 (PITX2)  b     rs11598047 (NEURL)   
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Supplementary	Figure	S9.	Enrichment	of	atrial	fibrillation	associated	loci	across	ChromHMM	
regulatory	regions	
	
	
	
	
	
Percent	overlap	of	loci	with	regulatory	regions	(promoter,	enhancer,	DNase)	based	on	Roadmap	
Epigenomics	Consortium	25-state	model	across	(a)	all	tissues	and	(b)	cardiac	tissues.	Each	locus	
includes	sentinel	variant	and	proxies	with	r2	>	0.6.	*P	<	0.005,	one-tailed	permutation	test	
(n=1,000).	1000G,	1000	Genomes	control	loci	matched	to	atrial	fibrillation	sentinel	SNPs	via	
SNPSnap	(n=93,000),	AF,	atrial	fibrillation	associated	loci	from	combined-ancestry	analysis	
(n=93),	sentinel	SNP	for	1	AF	locus	could	not	be	matched	in	SNPSnap	and	was	excluded	from	this	
analysis.	Whiskers	show	1.5	*	interquartile	range.	
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Supplementary	Notes	
	
Description	of	participating	studies	
This	manuscript	includes	the	following	studies	that	are	described	elsewhere:	The	Age,	
Gene/Environment	Susceptibility	Study	(AGES)	Reykjavik	study4,	the	Atrial	Fibrillation	Biobank	
LMU	(AFLMU)	in	the	context	of	the	Arrhythmia-Biobank-LMU4,	ANGES1,	the	Atherosclerosis	
Risk	in	Communities	(ARIC)	study4,	BEAT-AF1,	Biobank	Japan	(BBJ)5,	BioMe1,	Cleveland	Clinic	
Lone	Atrial	Fibrillation	GeneBank	Study	(CCAF)4,	the	Cardiovascular	Health	Study	(CHS)4,	
Corogene1,	Framingham	Heart	Study	(FHS)4,	FINCAVAS1,	GS:SFHS1,	LURIC1,	MDCS1,	MESA1,	
Massachusetts	General	Hospital	(MGH)	AF	study4,	MGH	CAMP1,	PIVUS1,	PREVEND1,	the	
PROspective	Study	of	Pravastatin	in	the	Elderly	at	Risk	(PROSPER)6,	the	Rotterdam	Study	(RS)4,	
SiGN7,	the	Study	of	Health	in	Pomerania	(SHIP)4,	SPHFC1,	TWINGENE1,	UK	Biobank8,	ULSAM1,	
the	Women’s	Genome	Health	Study	(WGHS)4		and	WTCCC2-Munich1.	Additional	studies	are	
described	as	follows:	
	
Australian	Familial	AF	Study:	A	cohort	of	probands	with	familial	AF	was	recruited	for	genetics	
studies	at	the	Victor	Chang	Cardiac	Research	Institute.	Familial	AF	cases	were	identified	from	in-
patient	and	outpatient	populations	at	St	Vincent’s	Hospital	and	by	referral	from	collaborating	
physicians	throughout	Australia.		Study	subjects	underwent	clinical	evaluation	with	history,	ECG	
and	echocardiogram,	and	informed	consent	was	obtained	from	all	participants.	151	probands	
aged	<66	years	at	the	time	of	diagnosis	were	included	in	this	analysis.	The	control	cohort	was	
comprised	of	age-	and	sex-matched	individuals	(n=151)	who	had	no	history	of	cardiovascular	
disease.	
	
Danish	AF	Study:	From	the	Danish	Study	of	Genetic	Causes	of	Atrial	Fibrillation	(DANFIB)	732	
patients	with	the	diagnosis	of	atrial	fibrillation	were	included.	The	enrolled	individuals	were	
identified	after	hospitalization	at	a	hospital	in	the	Copenhagen	area	and/or	through	a	
nationwide	search	using	the	Danish	National	Registries.	Individuals	who	accepted	participation	
had	blood	samples	drawn,	and	clinical	information	were	obtained	through	questionnaires	and	
subsequently	review	of	available	electronic	patient	health	records.	A	control	cohort	(n=534)	
without	the	diagnosis	of	atrial	fibrillation	was	recruited	from	the	Copenhagen	area.	All	enrolled	
participants	provided	written	informed	consent.	
	
Duke	Biobank:	The	CATHeterization	GENetics	(CATHGEN)	biorepository	collected	biospecimens	
and	clinical	data	on	individuals	age	≥18	undergoing	cardiac	catheterization	for	concern	of	
ischemic	heart	disease	at	a	single	center	(Duke	University	Medical	Center)	from	2000-2010;	a	
total	of	N=9334	individuals	were	collected.	Samples	were	matched	at	the	individual	level	to	
clinical	data	collected	at	the	time	of	catheterization	and	stored	in	the	Duke	Databank	for	
Cardiovascular	Diseases	(DDCD).	Clinical	data	included	subject	demographics,	cardiometabolic	
risk	factors,	and	cardiac	history	including	symptoms,	age-of-onset	of	cardiovascular	diseases,	
coronary	anatomy	and	cardiac	function	at	catheterization,	laboratory	data,	and	yearly	follow-up	
for	hospitalizations,	vital	status,	and	medication	use	and	lifestyle	factors.	AF	cases	were	defined	
as	individuals	who	had	ever	had	AF	based	on	any	ECG	available	at	Duke	University	or	ICD-9	code	
for	AF	used	for	inpatient	or	outpatient	billing.	
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EAST	-	AFNET	4	biomarker	substudy	(EAST):	The	samples	used	here	were	taken	at	enrolment	
into	the	EAST	–	AFNET	4	trial	from	patients	consenting	to	participation	in	the	biomarker	
substudy.	EAST	-	AFNET	4	is	a	controlled	trial	comparing	early	rhythm	control	therapy	to	usual	
care	in	patients	with	recent	onset	atrial	fibrillation	(defined	as	first	diagnosis	≤	12	months	or	less	
before	randomization)	and	at	least	two	stroke	risk	factors	as	codified	in	the	CHA2DS2-VASc	
score.	Patients	are	enrolled	in	11	European	countries.	Detailed	information	is	available	at	
www.easttrial.org	and	in	the	published	design	paper9.	
	
EGCUT:	The	Estonia	biobank	is	a	population-based	cohort	of	the	Estonian	Genome	Center	at	the	
University	of	Tartu	(EGCUT),	which	was	established	in	2001.	Subjects	were	recruited	at	random	
and	represent	about	5%	of	the	Estonian	population.		
	
Genetics	in	AF	(GENAF):	The	Genetics	in	AF	(GENAF)	study	enrolled	individuals	with	early-onset	
lone	AF	before	age	50	in	Norway	between	2009	and	201610.	Early-onset	was	defined	as	
diagnosis	of	AF	before	age	50.	Lone	AF	was	defined	as	AF	in	the	absence	of	clinical	or	
echocardiographic	findings	of	cardiovascular	disease,	hypertension,	and	metabolic	or	pulmonary	
disease.	AF	was	documented	in	ECG.	All	participants	underwent	clinical	examination,	including	
ECG,	echocardiography,	and	blood	draw,	from	which	DNA	has	been	extracted.	The	study	
conforms	to	the	principles	of	the	Declaration	of	Helsinki	and	was	approved	by	the	Regional	
Ethics	Committee	(REK)	in	Norway	(Protocol	reference	number:	2009/2224-5).	All	included	
patients	gave	written	informed	consent.	
	
German	MI	Family	Study	(GerMIFS)	6:	The	study	consists	of	3,320	individuals	from	Southern	
Germany	that	underwent	coronary	angiography	and	cardiac	examination.	1,820	were	diagnosed	
to	have	coronary	artery	disease	with	at	least	75%	stenosis	of	at	least	one	coronary	segment	and	
served	as	cases.	1,500	individuals	were	free	of	coronary	artery	disease,	atrial	fibrillation,	
congestive	heart	failure,	valvular	heart	disease,	and	peripheral	vascular	disease	at	time	of	
enrollment	(control	cohort).	
	
Groningen	Genetics	of	Atrial	Fibrillation	(GGAF):	The	GGAF	cohort	(n=2207)	is	a	genotype	and	
phenotype	repository	of	individuals	with	AF	and	age-	and	sex-matched	controls	from	5	different	
sources.	All	studies	were	approved	by	the	ethical	committee,	and	all	individuals	provided	
written	informed	consent.	Individuals	with	AF	(n=1108)	were	included	in	3	registry	cohorts	at	
the	University	Medical	Center	(www.atrialfibrillationresearch.nl),	and	Maastricht	University	
Medical	Center	(AF-Risk	n=6).	The	AF-Risk	study	(ClinicalTrials.gov	Identifier:	NCT01510210)	is	an	
observational	hospital-based	cohort	(n=500;	in	GGAF	339)	to	seek	for	markers	of	severity	of	
atrial	remodeling	and	predict	outcome	of	a	rhythm	control	treatment	strategy.	Patients	with	a	
short	history	of	AF	were	included.	Detailed	phenotypic	information	was	collected,	including	non-
invasive	vascular	function	measurements,	body	surface	mapping,	and	detailed	information	on	
presence	or	progression	of	AF	during	5-years	follow	up	is	obtained	by	use	of	serial	ECGs,	24-hour	
Holter	monitoring	and	recordings	from	loop	recorders.	The	Young-AF	study	is	an	observational	
hospital-based	cohort	(n=500;	in	GGAF	311)	to	seek	describe	the	phenotypic	profile	of	patients	
with	AF	onset	at	age	<60	years	and	the	occurrence	of	AF	progression	during	5	years	follow	up.	
The	phenotypic	data	that	was	collected	is	similar	to	the	AF	risk	profile	study.	The	Biomarker	AF	
study	(ClinicalTrials.gov	Identifier:	NCT01510197)	is	an	observational	hospital-based	cohort	
(n=500;	in	GGAF	458)	to	identify	a	risk	profile	to	guide	AF	therapy	in	all-comers	with	AF.	The	
project	is	similar	in	design	as	the	AF	risk	profile	study,	with	a	few	modifications.	No	extra	
phenotypic	information	on	top	of	our	standard	clinical	AF	protocol	was	performed,	except	blood	
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sampling.	Age-	and	sex-matched	individuals	without	AF	(controls)	were	included	from	2	cohorts	
at	the	University	Medical	Center	Groningen.	The	GIPS	study	is	a	randomized-controlled	trial	
(n=380;	in	GGAF	362)	to	evaluate	the	effect	of	metformin	treatment	on	preservation	of	left	
ventricular	function	in	patients	without	diabetes	presenting	with	ST-segment	elevation	
myocardial	infarction	(STEMI).	Mean	left	ventricular	ejection	fraction	after	4	months,	assessed	
by	magnetic	resonance	imaging	was	53.1%,	and	the	use	of	metformin	compared	with	placebo	
did	not	improve	left	ventricular	ejection	fraction.11	The	PREVEND	cohort	study	
(www.prevend.org)	is	a	community-based	cohort	study	including	8592	inhabitants	of	the	city	of	
Groningen,	The	Netherlands.	PREVEND	is	one	of	the	AFGen	consortium	participants,	see	further	
for	more	details	on	cohort	description12.	In	the	GGAF	cohort	we	included	742	individuals	without	
AF,	not	previously	included	in	GWAS.	
	
Genetic	Risk	Assessment	of	Defibrillator	Events	(GRADE):		GRADE	(The	Genetic	Risk	Assessment	
of	Defibrillator	Events)	study,	designed	to	identify	genetic	modifiers	of	arrhythmic	risk.	Inclusion	
criteria	were:	patients	who	were	≥18	years	of	age	with	a	diagnosis	of	at	least	moderate	systolic	
left	ventricular	dysfunction	(EF	≤30%),	and	who	had	an	ICD	at	the	University	of	Pittsburgh	
Medical	Center,	Emory	University	Medical	Center,	Massachusetts	General	Hospital,	Ohio	State	
University	Medical	Center,	Mid-Ohio	Cardiology	or	the	Pittsburgh	Veterans	Affairs	Medical	
Center.	Subjects	were	excluded	if	they	had	intractable	Class	IV	heart	failure,	and	conditions	
(other	than	HF)	that	were	expected	to	limit	survival	to	less	than	6	months.	The	institutional	
review	boards	of	participating	medical	centers	approved	the	study	and	each	patient	gave	
written	informed	consent	prior	to	participation.	This	study	was	conducted	according	to	the	
guidelines	laid	down	in	the	Declaration	of	Helsinki	and	the	trial	was	registered	at	
www.clinicaltrials.gov	(NCT	02045043).	
	
Hopkins:	The	Johns	Hopkins	University	School	of	Medicine	Atrial	Fibrillation	Genetics	Cohort	
started	collecting	data	in	September	2008	on	patients	>18	years	of	age	that	were	referred	for	
catheter	ablation	of	symptomatic	drug	refractory	atrial	fibrillation.	De-identifiable	patient	
samples	and	clinical	information	were	collected	prior	to	ablation	procedures.	
	
Heart	and	Vascular	Health	Study	(HVH):	The	Heart	and	Vascular	Health	Study	(HVH)	is	a	case-
control	study	of	risk	factors	for	development	of	cardiovascular	disease,	conducted	in	the	setting	
of	Group	Health	Cooperative,	a	large	integrated	healthcare	system	in	Washington	State,	USA.	In	
the	AF	study,	plan	members	assigned	a	new	ICD-9	code	of	427.31	or	427.32	in	the	inpatient	or	
outpatient	setting	during	2001-2007	were	identified.	Incident	AF	was	verified	by	review	of	
medical	records	with	the	requirement	that	the	AF	be	documented	by	12-lead	electrocardiogram	
and	clinically	recognized	by	a	physician,	with	no	previous	evidence	of	AF	in	the	medical	record.	
Control	subjects	were	identified	from	the	Group	Health	membership,	and	had	no	history	of	
atrial	fibrillation	by	medical	record	review.	All	subjects	had	an	index	date.	For	cases	the	index	
date	was	the	date	of	AF	diagnosis.	Control	subjects	were	assigned	an	index	date	from	the	
distribution	of	case	index	dates.	Controls	were	matched	to	AF	cases	on	age,	sex,	race,	treated	
hypertension	status,	and	year	of	identification.	Only	individuals	age	30	years	or	older	and	who	
self-identified	as	white	were	included	in	this	analysis.	
	
Incor	Warfarin	Study:	Participants	for	the	Incor	Warfarin	Study	were	prospectively	enrolled	
from	the	outpatient	clinic	at	the	Heart	Institute,	the	University	of	Sao	Paulo	Medical	School,	Sao	
Paulo,	Brazil.	Only	patients	older	than	18	years	and	in	current	use	of	warfarin	were	enrolled.	
This	is	a	cross-sectional	study	that	included	patients	treated	with	warfarin	for	at	least	12	
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months,	prior	to	enrollment,	at	the	Heart	Institute	(Incor),	University	of	São	Paulo,	São	Paulo,	
Brazil.	They	were	enrolled	in	two	different	time	periods:	from	September	2011	to	March	2012	
and	from	January	2014	to	February	2014.	Main	indications	for	treatment	with	warfarin	therapy	
were	atrial	fibrillation	or	flutter	(59.3%),	previous	cerebrovascular	accident	(12.8%),	thrombosis	
or	embolus	(6.3%)	and	use	of	prosthetic	heart	valves	(excluding	mechanical	valves)	requiring	
chronic	anticoagulation	(13.5%).	Atrial	fibrillation	status	was	determined	if	either	atrial	flutter	or	
atrial	fibrillation	was	present	on	a	12-lead	ECG	at	baseline	evaluation	or	prior	and	could	be	
confirmed	by	electronic	medical	record	review13.	
	
Intermountain:	The	INtermountain	Healthcare	Biological	Samples	Collection	Project	and	
Investigational	REgistry	for	the	On-going	Study	of	Disease	Origin,	Progression	and	Treatment	
(Intermountain	INSPIRE	Registry)	purpose	is	to	collect	biological	samples,	clinical	information	
and	laboratory	data	from	Intermountain	Healthcare	patients.	The	registry	originally	collected	
samples	in	patients	undergoing	a	coronary	angiography	as	part	of	the	Intermountain	Heart	
Collaborative	Study.	It	has	been	expanded	to	collect	samples	in	patients	diagnosed	with	all	types	
of	medical	conditions,	and	patients	from	the	general	population	including	those	who	have	not	
been	diagnosed	with	health	related	issues.	Just	over	25,000	individuals	have	provided	samples	
as	part	of	this	registry.	The	registry	enables	researchers	to	develop	a	comprehensive	collection	
of	information	that	may	help	in	disease	management,	including	determining	best	medical	
practices	for	predicting,	preventing	and	treating	medical	conditions.	
	
Maastricht	AFCT:	The	purpose	of	this	study	was	to	determine	the	prevalence	of	coronary	artery	
disease	(CAD)	in	patients	diagnosed	with	idiopathic	paroxysmal	AF14.	Of	the	patients	who	
underwent	cardiac	computed	tomographic	angiography	(CTA)	in	our	center	between	January	
2008	and	March	2011,	we	identified	a	total	of	115	consecutive	idiopathic	paroxysmal	AF	
patients	who	underwent	CTA	before	electrophysiologic	ablation.	Patients	were	compared	with	
age-,	sex-,	and	PROCAM	risk	score-matched	healthy	controls	in	permanent	sinus	rhythm.	All	
patients	were	free	of	hypertension,	diabetes,	congestive	heart	failure,	previous	known	coronary	
artery	and	peripheral	vascular	disease,	previous	stroke,	thyroid,	pulmonary,	and	renal	disease,	
and	structural	abnormalities	on	echocardiography.	
	
MGH	-	DOFEGEN:	The	Genetics	of	QT	Prolongation	with	Antiarrhythmics	(DOFEGEN,	
ClinicalTrials.gov	identifier	NCT02439658)	is	an	observational	study	of	subjects	admitted	to	
Massachusetts	General	Hospital	for	initiation	of	the	anti-arrhythmic	medications	dofetilide	and	
sotalol,	with	the	purposes	of	obtaining	pharmacogenomic	information	regarding	drug-induced	
effects	on	the	QT	interval.		The	medications	were	initiated	for	either	atrial	fibrillation	or	
ventricular	tachycardia/fibrillation,	and	subjects	underwent	repeated	ECGs	during	the	
hospitalization,	which	were	reviewed	by	cardiologists	for	underlying	rhythm	and	validation	of	
computer-measured	intervals.		The	study	is	presently	enrolling,	although	66	subjects	were	
included	for	this	investigation.	
	
MGH	Stroke	Study:	The	Genetics	of	Cerebral	Hemorrhage	on	Anticoagulation	(GOCHA)	study	is	
a	multicenter	study	of	the	genetics	of	intracerebral	hemorrhage	in	the	USA,	based	at	the	
Massachusetts	General	Hospital.	The	cases	are	individuals	presented	with	acute	primary	
hemorrhagic	stroke,	aged	more	than	55	years.	The	controls	were	recruited	from	ambulatory	
clinics	in	the	same	centers	in	which	cases	were	enrolled.	The	Genes	Affecting	Stroke	Risk	and	
Outcome	Study	(GASROS)	is	a	single-center	prospective	cohort	that	enrolled	cases	with	acute	
ischemic	stroke,	aged	more	than	18	years	who	presented	to	MGH	from	2003	to	2011.	Ischemic	
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stroke	was	defined	as	a	clinical	syndrome	of	associated	with	a	radiographically	proven	acute	
infarction	consistent	with	a	vascular	pattern	and	without	radiographic	evidence	of	a	
demyelinating	or	neoplastic	disease	or	other	structural	disease.		In	all	subjects,	the	diagnosis	
was	confirmed	by	diffusion	weighted	imaging	(DWI)	completed	within	48	hours	after	symptom	
onset.	Only	patients	of	self-reported	European	ancestry	were	enrolled.	Controls	were	matched	
to	cases	on	the	basis	of	age,	sex	and	race/ethnicity.	In	both	GOCHA	and	GASROS,	AFib	status	
was	determined	by	reviewing	medical	records,	and/or	interview	subjects	or	their	families.	The	
diagnosis	of	AFib	was	established	if	the	subject	either	had	a	pre-existing	diagnosis	or	was	
diagnosed	with	AFib	in	the	hospital.	The	diagnosis	was	not	confirmed	by	ECG	in	all	cases.	
	
MPP:	The	Malmö	Preventive	Project	(MPP)	was	a	community-based	disease	prevention	program	
including	33	346	inhabitants	from	the	city	of	Malmö	in	Southern	Sweden.	Complete	birth	
cohorts	between	1921-1949	were	invited,	and	the	participation	rate	was	71%.	Participants	
underwent	screening	between	1974	to	1992	for	cardiovascular	risk	factors,	alcohol	abuse,	and	
breast	cancer.	Between	2002-2006,	surviving	participants	were	invited	to	a	reexamination	which	
included	blood	sampling15	from	which	DNA	has	been	extracted.	Subjects	with	prevalent	or	
incident	AF	were	identified	from	national	registers	as	previously	described16,	and	cases	with	
DNA	were	then	matched	in	a	1:1	fashion	to	controls	with	DNA	from	the	same	cohort	by	sex,	age	
(±1	year),	and	date	of	baseline	exam	(±1	year).	Also,	controls	required	a	follow-up	exceeding	
that	of	the	corresponding	AF	case.	
	
Myocardial	Applied	Genomics	Network	(MAGNet)	repository:	The	MAGNet	respository	
(http://www.med.upenn.edu/magnet/)	includes	samples	from	normal	donors	at	the	time	of	
cardiac	transplantation.	The	study	protocol	was	approved	by	the	Institutional	Review	Board	at	
the	University	of	Pennsylvania,	and	all	patients	provided	written	informed	consent	to	
participate.	
	
Partners	HealthCare	Biobank	(PHB):	The	Partners	HealthCare	Biobank	is	a	large	research	data	
and	sample	repository	that	is	embedded	within	the	framework	of	Partners	Personalized	
Medicine.	The	Partners	Biobank	provides	banked	samples	(plasma,	serum,	DNA	and	buffy	coats),	
genomic	data,	and	other	health	information,	including	data	from	the	Electronic	Medical	Record	
(EMR).	Using	the	Research	Patient	Database	Query	Tool,	a	large	database	of	detailed	Partners	
HealthCare	electronic	health	record	data,	we	applied	a	validated	electronic	AF	ascertainment	
algorithm17	to	identify	unique	cases	of	AF.	Briefly,	the	AF	algorithm	utilizes	diagnostic,	
procedure,	electrocardiographic,	and	medication	data	to	ascertain	the	presence	of	atrial	flutter	
or	fibrillation.	
	
Penn	Medicine	Biobank	(Penn):	The	Penn	Medicine	BioBank	was	started	in	2009	and	aims	to	
recruit	patients	within	the	University	of	Pennsylvania	Health	System	to	donate	venous	blood.		All	
samples	are	linked	to	de-identified	electronic	medical	records.	Participation	is	completely	
voluntary	and	written	and	informed	consent	are	obtained	prior	to	sample	collection.	For	this	
project,	all	samples	were	collected	within	the	inpatient	and	outpatient	sections	of	the	
cardiovascular	division	at	the	University	of	Pennsylvania.	AF	cases	were	limited	to	adults	>18	
years	of	age.	AF	was	ascertained	through	an	ICD-9	diagnosis	of	atrial	fibrillation,	atrial	flutter	or	
documentation	within	the	medical	record.	
	
Texas	Cardiac	Arrhythmia	Institute	(TCAI):	DECAF	trial	was	conducted	at	TCAI	in	2013	in	
collaboration	with	University	of	Texas	at	Austin.	Four	hundred	consecutive	AF	patients	
GWAS	for	Atrial	Fibrillation	
Page	29	of	38	
undergoing	catheter	ablation	were	enrolled.	All	participants	provided	voluntary	informed	
consents.	Blood	samples	were	collected	before	the	ablation	procedure	and	labeled	with	
anonymous	patient	identifier.	The	researchers	at	UT	Austin	responsible	for	DNA	extraction	and	
genetic	analysis	were	blinded	about	the	clinical	characteristics	and	identification	of	the	study	
participants.	AF	cases	included	adults	>18	years	of	age	from	both	sex	and	all	AF	types18.	
	
UCSF:	The	University	of	California	San	Francisco	(UCSF)	Cardiovascular	Research	Institute	(CVRI)	
Resource	in	Arteriosclerosis	and	Metabolic	Disease	is	an	ongoing	multi-ethnic	study	of	adults	
≥18	years	of	age	which	was	started	in	1989	and	now	includes	28,000	participants	recruited	from	
the	UCSF	medical	system.	Within	the	Resource	lies	data	and	biospecimens	from	nearly	1,000	
patients	presenting	to	the	electrophysiology	laboratory	for	electrophysiology	procedures	that	
were	densely	phenotyped	for	electrophysiologic	characteristics	with	biospecimens	collected	
from	various	intra	and	extra-cardiac	chambers.	Phenotyping	of	all	participants	was	achieved	via	
interview	and	review	of	medical	records.	
	
UMass:	The	University	Of	Massachusetts	Medical	School	(UMMS)	Division	of	Cardiovascular	
Medicine	Research,	“Defining	time-dependent	genetic	and	transcriptomic	responses	to	cardiac	
injury	among	patients	with	arrhythmias”	is	an	ongoing	study	of	any	adult	patient	≥18	years	of	
age	undergoing	an	elective	electrophysiology	study	or	arrhythmia	ablation	procedure	for	a	
supraventricular	or	ventricular	arrhythmia,	including	atrial	fibrillation	(AF).	Patients	may	be	in	
sinus	rhythm	or	atrial	fibrillation	at	the	time	of	the	procedure.		This	study	started	in	2011	and	
now	includes	580	participants	recruited	from	the	UMass	Memorial	HealthCare	Center	
(UMMHC).	De-Identifiable	patient	samples	and	clinical	information	were	collected	prior	to	
ablation	procedures.	Using	a	prospective	study	design,	we	quantified	plasma	expression	of	86	
miRNAs	using	high-throughput	quantitative	reverse	transcriptase-polymerase	chain	reaction	
(RT-qPCR)	in	72	patients	undergoing	ablation	for	symptomatic	AF	and	followed	through	the	
UMMHC	AF	Treatment	Program.	The	72	participants	completed	a	standardized	follow-up	
regimen	over	12	months	following	ablation	and	were	included	in	the	analysis.	All	participants	
received	per-protocol	ECG	and	cardiac	rhythm	monitors	to	assess	for	AF	recurrence.	MiRNA	
levels	were	normalized	and	then	compared	between	participants	with	and	without	an	AF	
recurrence	over	the	12-month	follow-up	period.	
	
Vanderbilt	Atrial	Fibrillation	Registry:	The	Vanderbilt	Atrial	Fibrillation	Registry	is	a	clinical	
biorepository	for	patients	with	atrial	fibrillation.	Subjects	were	prospectively	enrolled	and	
longitudinally	followed	to	collect	data	on	disease	course	and	response	to	AF	therapy.	
	
Vanderbilt	AF	Ablation	Registry	(VAFAR):	The	Vanderbilt	Atrial	Fibrillation	Ablation	Registry	
(VAFAR)	is	a	prospective	observational	registry	of	subjects	undergoing	AF	ablation	
(clinicaltrials.gov	NCT	#02404415).	Written	informed	consent	is	obtained	prior	to	ablation.	DNA	
is	extracted	from	whole	blood	collected	during	the	procedure.	Baseline	clinical	data	is	manually	
extracted	from	the	medical	record	and	supplemented	by	patient	interview.	Subjects	are	
prospectively	followed	for	arrhythmia	recurrence	post-ablation	according	to	current	guidelines.	
		
Vanderbilt	BioVU:	BioVU	is	the	Vanderbilt	University	Medical	Center's	biorepository	linked	to	
de-identified	electronic	health	records.	BioVU	operations19	and	ethical	oversight20	have	been	
described	elsewhere.	Briefly,	DNA	is	collected	from	discarded	blood	samples	remaining	after	
routine	clinical	testing	at	Vanderbilt	outpatient	clinics	in	Nashville,	Tennessee	and	surrounding	
areas,	and	is	linked	to	a	de-identified	version	of	the	patient's	electronic	health	record	termed	
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the	“Synthetic	Derivative.”	AF	cases	were	defined	as	individuals	who	were	aged	>18	years,	had	
an	ICD-9	diagnosis	for	AF	or	flutter	(ICD-9:	427.3,	427.31,	and	427.32),	or	a	cardiologist	diagnosis	
of	AF	as	identified	by	a	natural	language	processing	tool	from	the	unstructured	free	text	of	the	
ECG	impression.	In	all	instances,	patients	with	a	history	of	a	heart	transplant	were	excluded	
(Current	Procedural	Terminology:	33935,	3394,	and	580;	ICD-9:	V42.1,	996.83).	
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